OICR welcomes Government of Canada's announcement of support for cancer control

NewsGuard 100/100 Score

Dr. Tom Hudson, President and Scientific Director of the Ontario Institute for Cancer Research (OICR) today welcomed the Government of Canada's announcement of support for cancer control with a renewal of the mandate of the Canadian Partnership Against Cancer (CPAC) for five years and $250 million in funding.

"We are very pleased to see the excellent support that CPAC has received from the federal government. CPAC initiatives to reduce the burden of cancer will have a significant impact on all Canadians. The continued mandate and new funding will allow us to continue our important collaboration with CPAC on the Ontario Health Study (OHS) and other initiatives," said Dr. Hudson.

The OHS is a participating study of CPAC's Canadian Partnership for Tomorrow Project, which consists of a further four regional studies across Canada. The aim of these studies is to investigate the factors that increase individual and community risk of developing cancer, heart disease, diabetes, asthma, Alzheimer's disease and other common diseases.

Dr. Lyle Palmer, Executive Scientific Director, Ontario Health Study said, "Building healthier communities is the mission of the Ontario Health Study - whether it's through active health promotion or through innovative population health research that will build the healthier communities of tomorrow. It is because of studies like this one that we know that there is a link between cancer and smoking. I encourage everyone in Ontario who is at least 18 years old to join the Ontario Health Study and leave a similarly profound legacy for future generations."

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
New research pinpoints key pathways in prostate cancer's vulnerability to ferroptosis